



## Nanotechnology-Based Approaches for Chronic Diseases

Guest Editors:

**Dr. Palanivel Ganesan**

palanivel@kku.ac.kr

**Dr. Karthivashan  
Govindarajan**

karthivashan@gmail.com

**Prof. Dr. Dong-Kug Choi**

choidk@kku.ac.kr

Deadline for manuscript  
submissions:

**closed (31 October 2019)**

### Message from the Guest Editors

Chronic diseases like neurodegenerative diseases, cancers, diabetes, arthritis, cardiovascular diseases and so on are rapidly increasing worldwide. Despite this, the treatment for the chronic neuronal complications is still limited due to the difficulty for drugs to cross the blood–brain barrier, which has led researchers to search for novel medicines with a lower particle size. Similarly, other chronic diseases are also facing problems in the delivery of drug or other bioactive compounds to the target site. Nanotechnology-based medicines are currently in the pipeline for the effective delivery of those drugs with a lower particle size and the enhanced bioavailability of these drugs. The nanotechnology-based delivery of drug or bioactive compounds is an emerging trends in the protection, treatment or prevention of chronic diseases.

Thus, this Special issue focuses on but is not limited to the following key sectors:

- Nanodelivery system development for chronic diseases
- Nanotechnologies used for drug development like micronization
- Nanotechnology-based molecular interactions
- Targeted nanomedicines
- Nanotoxicology
- Nanoimaging





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Yvonne Perrie

Strathclyde Institute of Pharmacy  
and Biomedical Sciences,  
University of Strathclyde,  
Glasgow G4 0RE, UK

## Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

## Author Benefits

**Open Access:**— free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Pharmaceutical Science*)

## Contact Us

---

*Pharmaceutics*  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/pharmaceutics](http://mdpi.com/journal/pharmaceutics)  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)  
[@MDPIpharma](https://twitter.com/MDPIpharma)